Otenabant

Summary

Otenabant (CHEMBL562668) is a phase-3 clinical-stage small molecule targeting CNR1; indicated across 1 condition including obesity disorder.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Targets: 1 (CNR1)
• Indications: 1 condition
• Clinical trials: 9
• Chemistry: 510.4 Da · C25H25Cl2N7O

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL562668
Name	Otenabant
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	10052040
Molecular formula	C25H25Cl2N7O
Molecular weight	510.4
InChIKey	UNAZAADNBYXMIV-UHFFFAOYSA-N

SMILES: CCNC1(CCN(CC1)C2=NC=NC3=C2N=C(N3C4=CC=C(C=C4)Cl)C5=CC=CC=C5Cl)C(=O)N

IUPAC name: 1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)purin-6-yl]-4-(ethylamino)piperidine-4-carboxamide

Also known as: CP-945,598, Cp-945598, CP-945598, Otenabant, Otenabant hydrochloride, otenabant, OTENABANT

Parent form; salt/anhydrous children: CHEMBL2103817, CHEMBL3526399

Patent coverage: 97 distinct patent families (243 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
CNR1	CB1 receptor	Inverse agonist	9.15	0%	P21554

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: Cannabinoid receptor 1, Cannabinoid receptor 2, Cannabinoid receptor 1.

Bioactivity

ChEMBL activities: 5 potent at pChembl ≥ 5 of 5 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
CNR1	9.92	Ki	0.12	nM	CHEMBL_ACT_2249688
CNR1	9.15	Ki	0.7	nM	CHEMBL_ACT_18588931
CNR1	9.15	Ki	0.7	nM	CHEMBL_ACT_2249680
P20272	8.55	Ki	2.8	nM	CHEMBL_ACT_2249672
CNR2	5.11	Ki	7700	nM	CHEMBL_ACT_18588963

Target pathways

Aggregated over 1 target gene(s): CNR1.

Top Reactome pathways

2 total, by targets touching each:

Pathway	Targets	Genes
Class A/1 (Rhodopsin-like receptors)	1	CNR1
G alpha (i) signalling events	1	CNR1

Dominant GO biological processes

GO term	Targets
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	1
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	1
adenylate cyclase-activating G protein-coupled receptor signaling pathway	1
axonal fasciculation	1
cannabinoid signaling pathway	1
glucose homeostasis	1
retrograde trans-synaptic signaling by endocannabinoid	1
regulation of presynaptic cytosolic calcium ion concentration	1
signal transduction	1
G protein-coupled receptor signaling pathway	1

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
obesity disorder	3	MONDO:0011122	EFO:0001073

Clinical trials

Total trials: 9.

Phase distribution

Phase	Trials
PHASE1	6
PHASE3	2
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00134199	PHASE2/PHASE3	COMPLETED	A Study Of 6-Month Duration To Evaluate The Weight Loss Effect Of Various Doses Of CP-945,598 In Obese Subjects
NCT00391196	PHASE3	TERMINATED	A 1-Year Study On The Effects Of CP-945,598 For The Treatment Of Obesity In Overweight Type 2 Diabetic Patients
NCT00483171	PHASE3	TERMINATED	A 14-Month Study On The Effects Of CP-945,598 For The Prevention Of Weight Regain In Obese Patients
NCT00472836	PHASE1	COMPLETED	Study Examining The Effect Of Renal Impairment On Safety, Toleration And How The Body Processes An Experimental Drug
NCT00644839	PHASE1	COMPLETED	Study Examing The Effect Of Omeprazole On Safety, Tolerability And How The Body Processes An Experimental Drug
NCT00645021	PHASE1	COMPLETED	Study Examining The Effect Of Hepatic Impairment On Safety, Toleration And How The Body Processes An Experimental Drug
NCT00645216	PHASE1	COMPLETED	Study Examing The Effect of Grapefruit Juice On The Blood And Urine Samples of Study Drug And Its By Product And Safety
NCT00645463	PHASE1	COMPLETED	Effect of Diltiazem Administration on CP-945,598 Pharmacokinetics
NCT01517100	PHASE1	COMPLETED	The Role of Endocannabinoids in Insulin Production and Action

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

124 molecules share ≥1 primary target. Top 100 by shared-target count:

Molecule	Source	Status	Shared targets
TAFAMIDIS	ChEMBL + PubChem	Phase 4 (approved)	CNR1
ACARBOSE	ChEMBL	Phase 4 (approved)	CNR1
ALCLOMETASONE DIPROPIONATE	ChEMBL	Phase 4 (approved)	CNR1
ALPRAZOLAM	ChEMBL	Phase 4 (approved)	CNR1
AMCINONIDE	ChEMBL	Phase 4 (approved)	CNR1
AMPRENAVIR	ChEMBL	Phase 4 (approved)	CNR1
ATENOLOL	ChEMBL	Phase 4 (approved)	CNR1
BECLOMETHASONE DIPROPIONATE	ChEMBL	Phase 4 (approved)	CNR1
BEPRIDIL	ChEMBL	Phase 4 (approved)	CNR1
BIFONAZOLE	ChEMBL	Phase 4 (approved)	CNR1
BUCLIZINE	ChEMBL	Phase 4 (approved)	CNR1
BUSPIRONE	ChEMBL	Phase 4 (approved)	CNR1
CAFFEINE	ChEMBL	Phase 4 (approved)	CNR1
CALCITRIOL	ChEMBL	Phase 4 (approved)	CNR1
CANDESARTAN CILEXETIL	ChEMBL	Phase 4 (approved)	CNR1
CANNABIDIOL	ChEMBL	Phase 4 (approved)	CNR1
CARBENOXOLONE	ChEMBL	Phase 4 (approved)	CNR1
CEFDINIR	ChEMBL	Phase 4 (approved)	CNR1
CHLORHEXIDINE	ChEMBL	Phase 4 (approved)	CNR1
CICLESONIDE	ChEMBL	Phase 4 (approved)	CNR1
DEXAMETHASONE	ChEMBL	Phase 4 (approved)	CNR1
DRONABINOL	ChEMBL	Phase 4 (approved)	CNR1
ECONAZOLE	ChEMBL	Phase 4 (approved)	CNR1
EFAVIRENZ	ChEMBL	Phase 4 (approved)	CNR1
ENZALUTAMIDE	ChEMBL	Phase 4 (approved)	CNR1
ERYTHROMYCIN	ChEMBL	Phase 4 (approved)	CNR1
ETHAMBUTOL	ChEMBL	Phase 4 (approved)	CNR1
FELODIPINE	ChEMBL	Phase 4 (approved)	CNR1
FENOFIBRATE	ChEMBL	Phase 4 (approved)	CNR1
FENTICONAZOLE	ChEMBL	Phase 4 (approved)	CNR1
FEXOFENADINE	ChEMBL	Phase 4 (approved)	CNR1
FLUOXETINE	ChEMBL	Phase 4 (approved)	CNR1
FLUSPIRILENE	ChEMBL	Phase 4 (approved)	CNR1
FLUTICASONE FUROATE	ChEMBL	Phase 4 (approved)	CNR1
GLIPIZIDE	ChEMBL	Phase 4 (approved)	CNR1
IMIPRAMINE	ChEMBL	Phase 4 (approved)	CNR1
INDOCYANINE GREEN ACID FORM	ChEMBL	Phase 4 (approved)	CNR1
KETOTIFEN	ChEMBL	Phase 4 (approved)	CNR1
LOFEPRAMINE	ChEMBL	Phase 4 (approved)	CNR1
LORCASERIN	ChEMBL	Phase 4 (approved)	CNR1
LOSARTAN	ChEMBL	Phase 4 (approved)	CNR1
MASOPROCOL	ChEMBL	Phase 4 (approved)	CNR1
MECLIZINE	ChEMBL	Phase 4 (approved)	CNR1
MEFLOQUINE	ChEMBL	Phase 4 (approved)	CNR1
MESTRANOL	ChEMBL	Phase 4 (approved)	CNR1
MIANSERIN	ChEMBL	Phase 4 (approved)	CNR1
MICONAZOLE	ChEMBL	Phase 4 (approved)	CNR1
MINAPRINE	ChEMBL	Phase 4 (approved)	CNR1
MITOTANE	ChEMBL	Phase 4 (approved)	CNR1
NABILONE	ChEMBL	Phase 4 (approved)	CNR1
NAFTIFINE	ChEMBL	Phase 4 (approved)	CNR1
NEBIVOLOL	ChEMBL	Phase 4 (approved)	CNR1
NIMODIPINE	ChEMBL	Phase 4 (approved)	CNR1
NISOLDIPINE	ChEMBL	Phase 4 (approved)	CNR1
ORLISTAT	ChEMBL	Phase 4 (approved)	CNR1
PAROXETINE	ChEMBL	Phase 4 (approved)	CNR1
PERMETHRIN	ChEMBL	Phase 4 (approved)	CNR1
PILOCARPINE	ChEMBL	Phase 4 (approved)	CNR1
PRENYLAMINE	ChEMBL	Phase 4 (approved)	CNR1
PROCHLORPERAZINE	ChEMBL	Phase 4 (approved)	CNR1
PYRVINIUM	ChEMBL	Phase 4 (approved)	CNR1
RACECADOTRIL	ChEMBL	Phase 4 (approved)	CNR1
RALOXIFENE	ChEMBL	Phase 4 (approved)	CNR1
RIMEXOLONE	ChEMBL	Phase 4 (approved)	CNR1
RIMONABANT	ChEMBL	Phase 4 (approved)	CNR1
ROSIGLITAZONE	ChEMBL	Phase 4 (approved)	CNR1
ROTIGOTINE	ChEMBL	Phase 4 (approved)	CNR1
SELEXIPAG	ChEMBL	Phase 4 (approved)	CNR1
SERTINDOLE	ChEMBL	Phase 4 (approved)	CNR1
TAMOXIFEN	ChEMBL	Phase 4 (approved)	CNR1
TEGASEROD	ChEMBL	Phase 4 (approved)	CNR1
TETRACAINE	ChEMBL	Phase 4 (approved)	CNR1
VENLAFAXINE	ChEMBL	Phase 4 (approved)	CNR1
ZAFIRLUKAST	ChEMBL	Phase 4 (approved)	CNR1
AMBROXOL	ChEMBL	Phase 3	CNR1
BENIDIPINE	ChEMBL	Phase 3	CNR1
CAMOSTAT	ChEMBL	Phase 3	CNR1
CANNABINOL	ChEMBL	Phase 3	CNR1
DEXANABINOL	ChEMBL	Phase 3	CNR1
EPIGALOCATECHIN GALLATE	ChEMBL	Phase 3	CNR1
LENABASUM	ChEMBL	Phase 3	CNR1
LERCANIDIPINE	ChEMBL	Phase 3	CNR1
MANIDIPINE 6300	ChEMBL	Phase 3	CNR1
NITRENDIPINE	ChEMBL	Phase 3	CNR1
OTILONIUM BROMIDE	ChEMBL	Phase 3	CNR1
TARANABANT	ChEMBL	Phase 3	CNR1
BENZETHONIUM	ChEMBL	Phase 2	CNR1
CANNABIDIVARIN	ChEMBL	Phase 2	CNR1
CANNABIGEROL	ChEMBL	Phase 2	CNR1
CROCONAZOLE	ChEMBL	Phase 2	CNR1
DELTA-8-TETRAHYDROCANNABINOL	ChEMBL	Phase 2	CNR1
DOMIPHEN	ChEMBL	Phase 2	CNR1
FLUNARIZINE	ChEMBL	Phase 2	CNR1
IBIPINABANT	ChEMBL	Phase 2	CNR1
LOMERIZINE	ChEMBL	Phase 2	CNR1
NORDAZEPAM	ChEMBL	Phase 2	CNR1
PHENOTHIAZINE	ChEMBL	Phase 2	CNR1
PIZOTYLINE	ChEMBL	Phase 2	CNR1
PRAVADOLINE	ChEMBL	Phase 2	CNR1
PRS-211375	ChEMBL	Phase 2	CNR1